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Formulation, characterization and evaluation of
morusin loaded niosomes for potentiation of
anticancer therapy
Srishti Agarwal,a M. Sheikh Mohamed,a Sreejith Raveendran,b Ankit K. Rochani,c
Toru Maekawaa and D. Sakthi Kumar *a
Morusin, a water-insoluble prenylated ﬂavonoid is known for its numerous medicinal properties. It
manifests its anticancer potential by suppression of genes involved in tumor progression. However, poor
solubility of the drug results in low bioavailability and rapid degradation thus hindering its clinical
utilization. In order to overcome this, we have synthesized a niosome system composed of non-ionic
surfactant span 60 and cholesterol using a thin-layer evaporation technique to improve the aqueous-
phase solubility of the drug. Highly cytocompatible niosomes of 479 nm average size with smooth and
uniform spherical morphology were synthesized in a facile manner. Unlike free morusin, nanomorusin
was found to be freely dispersible in aqueous media. Having an extremely high drug entrapment
eﬃciency (97%), controlled and sustained release of morusin resulting in enhanced therapeutic eﬃcacy
was observed in cancer cell lines of 4 diﬀerent lineages. The results demonstrate that the morusin-
niosome system is a promising strategy for enhanced anti-cancer activity against multiple cancer types
and could be an indispensable tool for future targeted chemotherapeutic strategies.
Introduction
Cancer remains the principal cause of death in the world,
regardless of economic or nancial status of the respective
nations.1 Clinical cancer treatment is heavily dependent upon
chemotherapy in conjunction with radiation therapy and
surgery, with immunotherapy playing a supportive role. Despite
major advances in these treatment modules, high instances of
tumor relapse and long-term permanent side eﬀects remain
unaddressed. Generally, in order to impede the growth of
proliferating tumor cells, cytotoxic drugs are given which deter
the proliferation of cancer cells, but play a signicant role in
non-target toxicity resulting in unwanted and severe side
eﬀects.
Therefore, extensive research is being carried out on using
substances derived from natural origins as potent inhibitors of
cancer, which have roots in numerous traditional medicinal
regimes. Natural substances like curcumin,2,3 resveratrol,4,5
quercetin,6,7 and green tea catechins8,9 have displayed consid-
erable toxicity against various cancer types with minimal non-
target toxicity. However, with the rise of therapies that utilize
high throughput screening methods for production of phar-
maceutical molecules and drugs, the interest in natural prod-
ucts has declined rapidly.10
Despite showing tremendous results against few cancer
types, these therapies remained unsatisfactory for many solid
cancers due to undesired side-eﬀects, which redirected the
attention on natural products. Rapamycin, produced by the soil
bacterium Streptomyces hygroscopicus was the rst anticancer
natural product to be approved in 2007 followed by other
natural product derivatives.10,11 Being chemoprotective in
nature, these products are classied either as potent antioxi-
dants, phenolic or having reactive groups, which impart
protective properties.12
One such natural product is morusin, a prenylated avonoid
derived from the root bark ofMorus alba which has been stated
to possess anti-inammatory, anti-oxidant and anti-bacterial
activities.13 Eﬀectiveness of morusin as a potent anti-tumor
agent has been elucidated by a number of studies. Various
biological activities displayed by morusin include protection
against nitric oxide (NO)-induced neuroblastoma cell death,14
scavenging activity against superoxide anion radicals,15 anti-
diabetic activity,16 adipocyte diﬀerentiation,17 etc. Predomi-
nantly, morusin has shown cytotoxic eﬀects against cancer cell
lines including breast adenocarcinoma,18,19 colorectal adeno-
carcinoma,20 gastric cancer,21 etc. Recent studies have reported
inhibition of NF-kB and STAT-3 signaling by morusin in pros-
trate, pancreatic and liver cancer cells.22–24 In addition, morusin
aBio Nano Electronics Research Center, Graduate School of Interdisciplinary New
Science, Toyo University, Kawagoe, Saitama, 350-8585, Japan. E-mail: sakthi@toyo.
jp; Fax: +81-366-77-1140; Tel: +81-492-39-1636/1375/1640
bSchool of Pharmacy and Biomolecular Sciences, University of Brighton, Moulsecoomb,
Brighton, BN2 4GJ, UK
cJeﬀerson College of Pharmacy, Department of Pharmaceutical Science, Thomas
Jeﬀerson University, 1020 Locust Street, Philadelphia, PA-19107, USA
Cite this: RSC Adv., 2018, 8, 32621
Received 28th July 2018
Accepted 12th September 2018
DOI: 10.1039/c8ra06362a
rsc.li/rsc-advances
This journal is © The Royal Society of Chemistry 2018 RSC Adv., 2018, 8, 32621–32636 | 32621
RSC Advances
PAPER
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
1 
Se
pt
em
be
r 2
01
8.
 D
ow
nl
oa
de
d 
on
 1
0/
15
/2
01
8 
5:
14
:5
9 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e. View Article Online
View Journal  | View Issue
is also known to inhibit the expression of metalloproteinases
(MMP-2 and MMP-9), which are elevated in the tumor micro-
environment.24,25 These evidences though support morusin as
an eﬀective natural anticancer drug; its full potential has not
been explored mainly due to its poor aqueous solubility and
bioavailability. Hydrophobicity of therapeutic moieties is
a major issue in drug formulations, which results in rapid
clearance by the reticuloendothelial system (RES) and poor
bioavailability, restricting their full clinical potential. Addi-
tionally, non-specic accumulation of the toxic compounds
cannot be monitored or controlled, leading to side eﬀects.
Nanotechnology oﬀers solutions for such limitations by
providing a stable reservoir for hydrophobic compounds, and
also minimizing oﬀ-site interactions, apart from assisting in
escaping the RES and reaching the target cells with high
precision.26 Numerous examples of nano-medicine
formulations exist in literature27–30 with continuous updates
on a near to daily basis. Of these, micellar systems have
attracted much attention due to their unique properties and
enhanced biocompatibility. These are a class of colloidal nano-
carriers comprising liposomes or niosomes, which are known to
possess signicant advantages over conventional dosage
forms.31 Niosomes are novel drug delivery carriers having
a bilayer that can either be unilamellar, or bi-lamellar
composed of various non-ionic surfactants and cholesterol.
Due to the availability of a variety of non-ionic surfactants, the
vesicles can be designed accordingly.32 Compared to other
surfactants, spans and tweens are known to have higher
entrapment eﬃciency and better release characteristics.33,34
Niosomes oﬀer prime advantages like ease of preparation,
reduced toxicity, increased stability, protection against degra-
dation of active drug molecules, and enhanced bioavailability
compared to liposomes, which have issues with physical and
chemical stabilities.32,35,36 Due to their unique and desirable
properties, niosomes have been in use as a part of the cosmetic
industry since 1970.37 The drugs can either be entrapped in
aqueous core (hydrophilic) or bilayer (hydrophobic) due to
presence of two distinct types of microenvironments.36 Drug
delivery using niosomes has been achieved using diﬀerent
modes of administration like intramuscular,38 intravenous,39
transdermal,40 etc. and niosomes have been employed for
delivery of various chemotherapeutic drugs like curcumin,36
cisplatin,41 doxorubicin,42 paclitaxel,43 etc. It has been specied
that entrapment of drugs inside a niosomal nano carrier can
prevent the uctuations in drug plasma concentration thus
achieving controlled drug delivery and reduced systemic toxicity
of anticancer drugs.31
As far to our knowledge, there is no study reporting morusin
as a nano formulation for curbing cancer growth. The present
study was formulated to obtain a robust drug delivery system for
encapsulating morusin in nanoparticles and accordingly,
a facile synthesis route was employed for producing morusin
niosomes and their cytotoxic and cellular localization studies
performed to assess the feasibility of this nanoformulation as
a potential anti-cancer candidate. We also performed docking
studies to observe binding of morusin to matrix metal-
loproteinases (MMP-2) and (MMP-9) which are up regulated in
the tumor milieu in pancreatic cancer,44 colorectal cancer,45
ovarian cancer46,47 and breast cancer,48,49 etc. thus contributing
to tumor progression and metastasis.
Experimental section
Materials
Span 60 (sorbitan monostearate) and cholesterol were procured
from Tokyo chemical industry Co. Ltd. Morusin was purchased
from Chemfaces. Chloroform was purchased from Kanto
chemicals, Japan. Human triple negative breast cancer (MDA-
MB-453), colorectal adenocarcinoma (HT-29), ovarian cancer
(SKOV-3), pancreatic cancer (PANC-1) cell lines and Mc-coy
medium were purchased from American Type Culture Collec-
tion (ATCC), USA. Mouse broblast cell lines (L929) was
purchased from Riken BioResource Center, Japan. Dulbecco's
modied Eagle's medium (DMEM), trypsin (0.25%), fetal bovine
serum (FBS), penicillin (5000 mg ml1)/streptomycin (5000 mg
ml1) and phosphate buﬀer saline (PBS) were procured from
Gibco (Life Technologies). Alamar blue cell viability kit reagent
was purchased from Invitrogen, USA. Live/dead viability/
cytotoxicity kit, Leibovitz media, Lysotracker deep red and
Nuc blue live ready probes reagent were acquired form Thermo
Fisher Scientic. All other chemicals and solvents were of
analytical grade.
Methods
Preparation of niosomes. Drug loaded niosomes were
synthesized using thin layer evaporation method with slight
modications.32 Briey, 100 mg of span 60, 20 mg of cholesterol
and 10 mg of drug (morusin) were dissolved in 20 ml of chlo-
roform. The solution was kept for intermittent stirring with
a magnetic stirrer for 1 h. Aer 1 h, the resultant solution was
kept for evaporation in a rotary evaporator for 1 h, which results
in formation of a thin lm. In order to get a completely dried
lm the ask was kept in a vacuum desiccator for 1 h. The
obtained thin lm was then hydrated using 20 ml of ultrapure
distilled water and 4 cycles of heating and vortexing (3 min
each) were performed in order to remove any residual chloro-
form from the solution. The resulting solution was then
centrifuged at 8000 rpm for 30 minutes for atleast 3 cycles in
order to concentrate down the particles. Aer discarding the
supernatant, the pellet was washed with ultra pure water thrice.
The product mor-nio (morusin-niosomes) was freeze dried and
stored at 20 C till further use. Void nio (devoid of morusin)
and C-6 nio (coumarin-6 loaded niosomes for cellular uptake
studies) were also synthesized similarly.
Determination of yield, entrapment and loading eﬃciencies.
The yield of niosomes was calculated by using the following eqn
(1)50
%Yield ¼ dry weight of the nanoparticles obtained
Wm þWspan 60 þWcholesterol
  100 (1)
where, Wm – weight of morusin, Wspan 60 – weight of span 60,
Wcholestrol – weight of cholesterol, used for niosome synthesis.
32622 | RSC Adv., 2018, 8, 32621–32636 This journal is © The Royal Society of Chemistry 2018
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The UV-Vis absorption spectra of free morusin, void nio and
mor-nio was recorded by UV-Vis spectrophotometer (DU730,
Beckman Coulter) for conrming entrapment of morusin. The
amount of free drug released in the supernatant was then
measured quantitatively against the calibration curve of the
drug and the unknown quantity was determined. Percentage of
entrapment eﬃciency was determined with a spectrophotom-
eter using the eqn (2)50
%Entrapment ¼ Ci  Cf
Ci
 100 (2)
where, Ci is the initial drug concentration used for preparation
of niosomes and Cf is the concentration of free drug in the
supernatant obtained upon washing.
Loading eﬃciency was determined using the formula (3)51
%Loading ¼ amount of drug in nanoparticles
gross weight of nanoparticles
 100 (3)
Niosome characterization. The size and morphological
analysis of the synthesized nanoparticles was done using
Hitachi SU6600 scanning electron microscope (SEM) and JEOL
JEM-2100 transmission electron microscope (TEM). Mor-nio
and void nio were dispersed in milliQ water for executing all
characterization experiments. For doing SEM analysis, 50 ml of
water-dispersed niosomes was dropped on a clean glass
substrate and vacuum dried. The dried sample was sputter
coated with platinum for 35 seconds (Hitachi E-1030, ion
sputter) and observed under SEM functioning at an accelerating
voltage of 10 kV. 100–125 individual particle diameters were
measured and the values were averaged to nd the mean
diameter value of the resulting particles. For TEM, 10 ml of
sample was placed on a hydrophilized Cu microgrid and air-
dried with observations performed at an accelerating voltage
of 100 kV. Particle size distribution and zeta-potential were
measured using zetasizer (Malvern, Nano-ZS). For particle size
distribution analysis, disposable polystyrene cuvettes were used
and the average diameter and polydispersity index (PDI) values
were acquired at 25 C. Zeta potential measurements were
carried out at 25 C using a dip cell. All size and zeta potential
measurements were carried out in triplicates.
In order to characterize the structure and explore the
chemical bonding patterns between morusin and the niosome
components (span 60 and cholesterol) Fourier Transform Infra-
Red Spectroscopy (FTIR) (Thermo Scientic, Nicolet iS50 FT-IR)
was performed. Samples were made into pellets using potas-
sium bromide (KBr) and subjected for analysis under trans-
mittance mode (4000–5001 cm).
In vitro drug release. In order to study the diﬀusion of
morusin from niosomes, drug release studies were carried out.
The nanoparticles were dispersed in phosphate saline buﬀer
(PBS) at two diﬀerent pH conditions of pH 4.5 and pH 7.4. All
experiments were carried out in triplicates. 15 mg of sample was
dispersed in 15 ml of PBS buﬀer and distributed in 15 Eppen-
dorf tubes such that concentration per tube was 1 mg ml1. All
tubes were kept at 37 C under a continuous shaking of 130 rpm
for 9 days. At predetermined time intervals, one tube was taken
out and centrifuged at 15 000 rpm/30 min. Absorbance of the
resulting supernatant was read by a UV-Vis spectrophotometer
at xed wavelength of the drug i.e. 269 nm and the amount of
morusin released was determined. The release kinetics was
calculated according to the following eqn (4)52
%Release ¼ released drug
total drug
 100 (4)
where ‘released drug’ is the concentration of the drug released
and collected at pre-dened time intervals and ‘total drug’ is the
amount of drug entrapped in the nanoparticles.
Cell culture. Human triple negative breast cancer (MDA-MB-
453), Human colorectal adenocarcinoma (HT-29), Human
pancreas ductal adenocarcinoma (PANC-1), Human ovarian
cancer (SKOV-3) and mouse broblast cell lines (L929) were
chosen to conduct in vitro cell studies and analyze the thera-
peutic eﬃcacy of mor-nio. PANC-1 cells along with SKOV-3 and
L929 were cultured in T-25 tissue culture asks in DMEM, HT-
29 in Mc-coy and MDA-MB-453 cells in Leibovitz media, sup-
plemented with 10% FBS, 1% penicillin/streptomycin at 37 C
in a humidied atmosphere of 5% CO2 and for MDA-MB-453
without CO2 till cells were 80% conuent. The cells were sub
cultured every 3–4 days or once the conuency was attained.
Cytocompatibility analysis. To assess whether the bare nio-
somes (void nio) exert any toxicity, cytocompatibility analysis
was performed. For the assay, conuent cells were trypsinized,
plated in a microtiter 96-well plate at a density of 8  103 cells
per ml and maintained at 37 C, 5% CO2 and for MDA-MB-453
without CO2. Aer incubation of 24 h, media was replenished
and void niosomes were added in the concentration range of 50
mg ml1, 100 mg ml1, 250 mg ml1, 500 mg ml1, and 1000 mg
ml1. Cells without nanoparticles were considered as controls.
Aer treatment with the desired concentration of void nio, the
cells were incubated for 6, 24 and 48 hours under respective
culture conditions. Aer dened incubation period, 10% ala-
mar blue dye (which monitors the reducing environment of
healthy cells and converts the non-uorescent resazurin (blue
color) to a highly uorescent reduced form resorun (red color)
indicative of metabolic activity of cells) was added to the cells
and plates were incubated for 4 hours following which uo-
rescence was recorded at 580–610 nm by a microplate reader
(Power scan HT Microplate reader, Dainippon Sumitomo
Pharma, Japan).
In vitro cytotoxicity studies. The therapeutic eﬃcacy of mor-
nio on diﬀerent cancer cell lineages and normal cells was
assessed using alamar blue. The assay procedure was similar to
previous section. Aer incubation of cells for 24 h, media was
replenished and free drug and mor-nio were added at varying
concentration (50 mg ml1, 100 mg ml1, 250 mg ml1, 500 mg
ml1, and 1000 mg ml1). The culture/data acquisition condi-
tions and parameters were similar as described in previous
section. Here we used free morusin in 0.5% DMSO, mor-nio and
untreated cells as control group for the experiment. The assay
was performed in three autonomous experiments all in tripli-
cates and cell viability was computed using the formula (5)51
This journal is © The Royal Society of Chemistry 2018 RSC Adv., 2018, 8, 32621–32636 | 32623
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%Cell viability ¼ Asample
Acontrol
 100 (5)
where Asample is the absorbance of the sample and Acontrol is the
absorbance of the control.
Internalization and co-localization of niosomes. The inter-
nalization of niosomes in L929, HT-29, PANC-1, SKOV-3 and
MDA-MB-453 was studied by confocal microscopy. As morusin
is non-uorescent, C-6 niosomes were utilized for the assay. The
cells were grown in respective growth media/culture condition
on 35 mm glass base culture dishes at a concentration of
approximately 5  104 cells for 24 h following which 100 mg
ml1 of C-6 nio was subsequently added to the cultures and
incubated for 2 hours. Aer incubation, the cells were washed
with 1, pH 7.4 PBS buﬀer to remove any excess unbound
particles. Lysotracker deep red and Nuc blue were then added to
the plates in order to stain the acidic compartments and nuclear
region, respectively according to product instructions. The cells
were examined using a high-speed confocal laser-scanning
microscope (CLSM, Nikon A1 plus Tokyo, Japan) at excitation
wavelengths of 402 nm (NucBlue), 488 nm (C6) and 630 nm
(Lysotracker).
Live/dead assay. The qualitative determination of live and
dead cells aer nanoparticle treatment was carried out using
CLSM. Cells at a density of 5  104 cells were plated in a 35 mm
glass base dishes for 24 h following which 500 mg ml1 of free
morusin, void nio, and mor-nio were added and incubated for
a further 24 h period. Post-incubation, cells were washed twice
with PBS and stained with live/dead viability/cytotoxicity
reagent as per product instructions. The plates were then
incubated at RT for 1 h following which the cells were observed
in CLSM at excitation and emission wavelengths of 495/515 nm
for calcein and 528/617 for EthD-1. The number of dead and
viable cells in the test was compared to the total number of
viable cells in the control.
Docking studies. In order to check the probable binding of
morusin to MMP-2 and MMP-9, molecular docking was
executed using Autodock 4.0 soware (USA). For performing
Docking simulations, we downloaded crystal structures of
proteins MMP9 (PDB id: 1GKC) andMMP2 (PDB id: 1CK 7) from
protein databank (pdb). Structure of ligand (Morusin) was
downloaded from PubChem (PubChem id: 5281671). Both
ligand and protein structures were subjected to geometry and
charge optimization using MMFF94 and Gasteiger charge
calculations. Essential hydrogen atoms, Kollman united atom
type charges, and solvation parameters were added with the aid
of AutoDock tools. Aﬃnity (grid) maps of 100  100  100 A˚
grid points and 0.375 A˚ spacing were produced using the
Autogrid program. AutoDock parameter set-and distance-
dependent dielectric functions were used in the computation
of the van der Waals and the electrostatic terms, respectively.
Docking simulations were accomplished using the Lamarckian
genetic algorithm (LGA) and the Solis & Wets local search
method. Initial position, orientation, and torsions of the ligand
molecules were set randomly. All rotatable torsions were
released during docking. Each docking experiment was derived
from 100 diﬀerent runs that were set to terminate aer
a maximum of 2 500 000 energy evaluations. The population
size was set to 150. During the search, a translational step of 0.2
A˚, and quaternion and torsion steps of 5 were applied. We
selected ligand–protein complexes that oﬀered most stable
conformations based on lowest Gibbs binding energy. Short
range van der Waal and electrostatic interactions, hydrogen
bonding, entropy losses were included for energy-based auto-
dock scoring function (Morris et al., 1998). The results were
downloaded in pdb les and subjected to analysis using Drug
Discovery Studios soware.
Results and discussion
Morphological characterization of morusin loaded niosomes
Niosomes (void nio/mor-nio) were synthesized using thin-layer
evaporation method in order to enhance the bioavailability,
eﬃcacy and aqueous solubility of the drug. Span 60 was used as
an ionic surfactant and cholesterol as an additive for prepara-
tion of niosomes. Cholesterol imparts rigidity53 while span 60
protects the drug from proteolytic enzymes leading to higher
physical stability.54,55 The synthesized niosomes were then
characterized for their morphology, size distribution and
surface characteristics.
As shown in SEM micrograph (Fig. 1a and d), the void nio
(445 nm) and mor-nio (479 nm) have a uniform spherical
morphology with smooth surface characteristics. The vesicles
are formed due to self-assembly of the non-ionic surfactants
upon their interaction with the aqueous medium leading to
creation of a concentric bilayer structure having morphology
comparable to liposomes but without phospholipids which
imparts better stability.35,56 Similar observations were made in
TEM as well where smooth and spherical niosomes could be
visualized (Fig. 1b and e). Fig. 1c and f show Gaussian size
distribution of the void and mor-loaded nanoparticles wherein
majority particles in both cases lie in the size range of 400–
500 nm. Detailed characterization of the particles is provided in
Table 1. Further, dynamic light scattering (DLS) measurement
done for void and mor-nio conrmed nanoparticles with size
distribution in the range of 400–500 nm and z-average size of
445 nm and 479 nm which correlated with SEM and TEM
observations. Since, the approximate size of vesicles/micelles
for cellular uptake via the endocytic pathway is 100–500 nm,
our synthesized mor-nio fall in the desired range for successful
internalization by cancer cells.57,58
The cellular interaction and uptake of nanoparticles is
highly inuenced by the surface charge of nanoparticles.59
Studies have reported that negatively or positively charged
nanoparticles are more readily internalized as compared to
their uncharged counterparts.59 Although positively charged
nanoparticles have a rapid cellular uptake in comparison to
negatively charged nanoparticles, they are known to cause
hemolytic size-eﬀects and cytotoxicity to normal tissues.59,60
The synthesized void and mor-nio had a zeta potential of
14.2 and 19.8, respectively, denoting the stability of the
colloidal suspension of niosomes. This could be accredited to
the coulombic repulsion forces occurring from their surface
charge, which overcomes the van der Waals attractive forces
32624 | RSC Adv., 2018, 8, 32621–32636 This journal is © The Royal Society of Chemistry 2018
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between them.50 Table 1 depicts the physico-chemical
parameters of the prepared nanoformulations.
Drug entrapment
Hydration of thin lm of mor-nio was achieved using deionized
distilled water in order to obtain drug-loaded niosomes. The
hydration step is important for self-assembly of the surfactants
and cholesterol as tiny polymeric vesicles entrappingmorusin.61
Conrmation of entrapment eﬃciency was established using
Fig. 1 (a) SEMmicrograph of void nio (d) SEMmicrograph of mor-nio. (b) TEM image of void nio (e) TEM image of mor-nio (c and f) Gaussian size
distribution for void and mor-nio.
Table 1 Physico-chemical characterization of void and mor-nio
Characterization parameter Void nio Mor-nio
Z average diameter (nm) 445 479
Poly dispersity index (PDI) 0.3 0.29
Zeta potential (mV) 14.2 19.8
Drug loading — 7.69  0.14%
Entrapment eﬃciency — 97  1.25%
% Yield 38.46  1.31% 31.07  2.43%
This journal is © The Royal Society of Chemistry 2018 RSC Adv., 2018, 8, 32621–32636 | 32625
Paper RSC Advances
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
1 
Se
pt
em
be
r 2
01
8.
 D
ow
nl
oa
de
d 
on
 1
0/
15
/2
01
8 
5:
14
:5
9 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
UV-Vis absorption spectroscopy. Fig. 2a depicts the absorbance
of mor-nio in comparison with void nio and free morusin.
Morusin (free drug) shows lmax at wavelength 269 nm, where
a major peak was observed as shown in (Fig. 2a). Same peak was
observed in the case of mor-nio as well, depicting morusin
entrapment in niosomes. However the peak was not as prom-
inent as seen in the case of free drug which maybe due to the
small amount of drug entrapment inside the niosomal nano
carrier. The minor peak shis observed could be due to the
interaction of morusin with niosome constituents during
synthesis and encapsulation processes. In case of void nio, no
peak was observed. The entrapment eﬃciency of the particles
was around 97 1.256% for every batch of particles synthesized
with 70.55 mg of the drug getting encapsulated (loading
eﬃciency  7.69  0.14%) as seen in Table 1. It has been widely
reported that length of the alkyl chain of surfactants determines
the diameter of vesicles. Vesicles obtained from stearyl (C18)
chain are known to yield larger particles with higher entrap-
ment eﬃciencies,32 which can be seen from our results by the
use of span 60 as the surfactant. For every batch of nano-
particles synthesized, the encapsulation, yield and loading
eﬃciencies had consistent values. The prepared mor-nio was
totally water-dispersible as compared to free morusin, which is
insoluble in water.
Surface characterization of niosomes
In order to study the chemical nature of niosomes, we per-
formed FTIR spectroscopy studies. In the study, we used void
nio and free drug as controls for the comparative analysis of
chemical bonding properties and peak shis in our drug loaded
nano formulation. FTIR measures the selective absorption of
light by the vibration modes of specic chemical bonds in the
sample. Vibrations arising due to the functional groups are
involved in such interactions, which may alter frequency and
intensity.51,61 Fig. 2b shows overlay of spectra from morusin,
void nio and mor-nio. The small band around 2978 cm1 is
attributed to the C–H stretching, which may be caused due to
the –CH, –CH2 and –CH3 stretching vibrations characteristic of
morusin.62 However in case of void nio and mor-nio the band is
around 2913 cm1. Moreover the signals around 1645 cm1 and
1585 cm 1 can be observed in both drug and drug loaded
niosomes while it's completely absent in void nio. Additionally,
Fig. 2 (a) UV-absorption overlay spectra for free morusin, mor-nio and void nio. The characteristic peak for morusin is around 269 nm, which
could be also observed in mor-nio. The void nio provided a ﬂat proﬁle (b) FT-IR spectra of mor-nio in comparison to native morusin and void nio
as a control. (c) Sustained drug release proﬁle for morusin nano formulation. An enhanced release was observed in acidic pH establishing mor-
nio as an eﬀective drug delivery system for pH dependent dug release in cancer cells.
32626 | RSC Adv., 2018, 8, 32621–32636 This journal is © The Royal Society of Chemistry 2018
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we could also see signicant overlap in the spectra of void and
mor-nio, which suggests that the chemical nature of the nio-
some remains unaltered. The FTIR analysis implies that there
was no chemical interaction between the drug and the nano-
particle that could modify its chemical structure during the
study and morusin was only physically encapsulated in the
niosomes.
In vitro drug release
The drug release kinetics of mor-nio was studied using UV-Vis
spectrophotometer for a period of 9 days under controlled
conditions of 37 C with constant stirring at 130 rpm
throughout the experiment. The most important prerequisite
for a drug delivery vehicle is the slow and sustained release of
drug. Percentage of morusin released from mor-nio at pH 4.5
and pH 7.4 under in vitro conditions can be observed in Fig. 2c.
The drug release was biphasic with an initial burst release
happening at the start, around 1st h (8.5% – pH 7.4 and 11.4% –
pH 4.5) which can be attributed to the diﬀuse mechanism from
outer layers of niosomes as well as minute surface-bound drug
molecules.63 Morusin release from niosomes was perceived to
be pH dependent, resulting in a slow drug release at physio-
logical pH 7.4 and a higher release at acidic pH 4.5 (pH;
depicting the acidic endosomal compartment aer endocy-
tosis), which is a prerequisite for transport of anticancer drugs
in the acidic environment of cancer cells. Followed by burst
release, a gradual release curve was observed aer 24 h with
30.2% (21.32 mg) of drug being released till this point in acidic
pH. Aer 48 h, the drug release increased to 43.6% (30.80 mg). At
120 h, approximately 58.1% of morusin was released at acidic
condition however at physiological pH, only 43.3% was released
following which there was a stationary phase. The niosome
membrane ensures that the encapsulated drug crosses the
membrane, which causes slower and delayed release. Also the
amount of cholesterol included in the formulation aﬀects the
release kinetics, with high CH content causing slow release of
the drug from the vesicle due to decreased permeability of the
niosomal membrane but higher encapsulation eﬃciency that
can be seen in case of our mor-loaded niosomes where the
encapsulation eﬃciency was found to be around 97%.63
Cytocompatibility analysis
In order to determine whether the synthesized niosomes were
non-toxic or could aﬀect the growth of cells, we performed
compatibility analysis in normal and cancer cells. Studies have
proven niosomes to be safe without any cytotoxic eﬀects.34,64,65
As could be seen from (Fig. 3), the cellular viability was above
80% in all the cell lines even at high concentration of particles
(1000 mg ml1). Thus, we conrm the particles synthesized were
highly compatible to cells under study and could be utilized for
further bio-applications without any modications.
Cellular uptake of mor-nio
The uptake of niosomes by cancer cells was assessed using C-6
nio. Fig. 4 depicts the CLSM images of diﬀerent cell lines treated
with coumarin-6 loaded niosomes. The cells were incubated
with 100 mg ml1 of C-6 nio for 2 hours following which lyso-
tracker and nuc blue were added in order to stain the acidic
organelles and nucleus. The particles can be seen accumulated
predominantly in the cytoplasm as evident from the green
uorescence of coumarin-6 while controls show no uores-
cence, thereby negating any auto uorescence from the cells
themselves.
HT-29 (Fig. 4b) cells had higher accumulation of particles as
seen by strong green uorescence compared to other cells.
SKOV-3 (Fig. 4q) is also seen to have higher accumulation,
which can be seen in the nucleus also however the cells were
least susceptible to mor-nio treatment as seen from cytotoxicity
studies. In PANC-1 (Fig. 4g) and MDA-MB-453 (Fig. 4l) the
uorescent signals were weak signifying lower accumulation of
particles. However, MDA-MB-453 was fairly inhibited by mor-
nio treatment as shown in cytotoxicity study. These observa-
tions indicate that lower particle accumulation was enough to
exert signicant toxicity to the cells.
Also, the images conrmed the endosome-mediated entry of
particles as they can be readily seen accumulated in lysosomes
where overlapping signals of nanoparticles and lysosomes
could be visualized.
Therapeutic eﬃcacy of mor-nio
The sustained toxic eﬀect of the drug is stalled due to its poor
bioavailability, a desired property for successful anticancer
therapy. Therefore, to evaluate the therapeutic potential of mor-
nio in comparison to free drug; we carried out dose and time-
dependent in vitro cell viability studies using alamar blue
assay in HT-29, PANC-1, MDA-MB-453, SKOV-3 cells and L929
cells. Cells were subjected to ve diﬀerent concentrations (50 mg
ml1, 100 mg ml1, 250 mg ml1, 500 mg ml1, 1000 mg ml1) of
mor-nio and free morusin for 6, 24 and 48 hours. In cancer cell
lines, we could perceive instant cell death and reduced cell
viability within 24 hours when treated with mor-nio (Fig. 5).
However, at the lowest dose (50–100 mg ml1), the eﬀect was
comparatively less pronounced while maximum cytotoxic eﬀect
was observed at 1000 mg ml1 concentration aer 48 h. This
could be due to the fact that mor-nio were able to reach a ther-
apeutic concentration aer 48 hours to impart cytotoxic eﬀects
to cancer cells. Toxicity of free drug was performed keeping in
mind the amount of drug encapsulated in 1000 mg ml1 of mor-
nio i.e. 70.55 mg, which was calculated using eqn (2). Compared
to mor-nio, the free drug displayed less cytotoxicity towards
cancer cells which maybe due to its hydrophobicity indicating
the advantage of encapsulating the drug inside niosomal
carrier. In case of free morusin, the cell viability was - HT29
(48.4%). PANC-1 (62.77%), MDA-MB-453 (53.02%), SKOV-3
(62.84%) aer 24 h at 70.55 mg ml1 concentration (which is
the amount of drug entrapped in 1000 mg ml1 of mor-nio)
however a decline in viability was seen aer 48 h. On the
other hand, mor-nio decreased the cell viability to a signicant
level aer 24 h at 1000 mg ml1 compared to the free drug -HT29
(33.05%), PANC-1 (46.13%), MDA-MB-453 (39.93%), SKOV-3
(59.17%). As seen in drug release (Fig. 2c) at 24 h, 30.23%
(21.32 mg) was released in acidic environment while it increased
This journal is © The Royal Society of Chemistry 2018 RSC Adv., 2018, 8, 32621–32636 | 32627
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to 43.66% (30.80 mg) aer 48 h, thus correlating with the cyto-
toxicity data with an increase in cell death at 48 h due to
augmented release of the drug. The viability aer 48 h in case of
morusin niosomes was – HT29 (26.32%). PANC-1 (35.88%),
MDA-MB-453 (21.53%), SKOV-3 (46.3%) whereas in case of free
drug it was – HT29 (35.21%), PANC-1 (55.68%), MDA-MB-453
Fig. 3 Cytocompatibility of void niosomes tested against cancer (a) HT-29, (b) PANC-1, (c) MDA-MB-453 (d) SKOV-3, cells and normal cell line
(e) L929. The particles were highly cytocompatible as depicted by high viability in all cell lines even at highest concentration of particles used.
32628 | RSC Adv., 2018, 8, 32621–32636 This journal is © The Royal Society of Chemistry 2018
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Fig. 4 Confocal microscopy images demonstrating cellular internalization of coumarin-6 niosomes by cancer cells. The green ﬂuorescent
intensity from cells with C-6 nio was clearly evident, signifying the enhanced uptake of niosomes by cancer cells. Nuclei were stained with
NucBlue and lysosomes with lysotracker deep red to show nanoparticles co-localization. Scale bars represent 20 mm.
This journal is © The Royal Society of Chemistry 2018 RSC Adv., 2018, 8, 32621–32636 | 32629
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Fig. 5 Therapeutic eﬃcacy of morusin-loaded niosomes and free morusin towards (a and b) HT-29 (c and d) PANC-1 (e and f) MDA-MB-453 (g
and h) SKOV-3 and (i and j) L929 cell line. Compared to the free drug, more inhibition was observed in the case of morusin-loaded niosomes in all
cell lines.
32630 | RSC Adv., 2018, 8, 32621–32636 This journal is © The Royal Society of Chemistry 2018
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(43.77%), SKOV-3 (53.55%). Though, similar particle accumu-
lation was observed in case of L929 cells as well (Fig. 4v),
viability remained at approximately 80% (Fig. 5i and j). The
reason for this could be the high mitotic index (cell doubling
rate) of L929 compared to other cell lines which could have
limited the eﬀect of the drug when compared to rapidly dividing
cells.
HT-29 was seen to be the most susceptible cell line to mor-
nio treatment. NF-kB activation is known to promote tumor
progression in colorectal cancers. Lee et al.20 reported that
morusin was able to signicantly suppress constitutive activity
of NF-kB via classical pathway. Dephosphorylation of Akt, PDK1
and P13 was also observed along with activation of caspase 9
due to downregulation of XIAP expression, caspase-8, and -3
due to morusin treatment in colorectal cancer cells. Thus,
taking into account all the above factors, multiple pathways are
known to be involved in inducing apoptosis in HT-29 cells by
morusin which may be the reason of enhanced inhibition
observed by mor-nio treatment. In case of pancreatic cancer,
constitutive activation of STAT 3 has been reported causing
tumor cell survival, proliferation and metastasis. Inhibition of
STAT-3 and downregulation of its regulated gene products-IAP1,
IAP2, Bcl-2, survivin, cyclin, COX-2, VEGF, MMP-9 was seen in
pancreatic tumor cells in parallel with inhibition of JAK1, JAK2
upon morusin treatment leading to apoptosis.22
Triple negative breast cancers (TNBCs) are cancers that do
not express progesterone receptor (PR), estrogen receptor (ER),
and the HER2 isoform of epidermal growth factor receptor
(EGFR) and hence due to lack of a specic therapeutic target
triple negative breast cancers have limited treatment
options.66 Mor-nio was seen to signicantly reduce the cell
viability of MDA-MB-453, a triple negative breast cancer line
upon treatment. Morusin has been shown to increase expres-
sion of pro-apoptotic marker protein Bax, reduce anti-
apoptotic protein survivin as well as cause cleavage of cas-
pase 9, -3 and PARP in a dose and time dependent manner in
triple negative breast cancer cell lines indicating its ability at
targeting anti and pro-apoptotic signals that may increase
anti-cancer activity.19 The mechanism of action however
remains elusive and its known that STAT3 inhibition aﬀects
expression of downstream targets-Bax and survivin, so maybe
morusin works by inhibiting STAT 3 also. Despite inducing
apoptosis in breast cancer cells, apoptotic rate was low
compared with cytotoxicity rate for same concentration of
morusin which means morusin may induce other types of cell
death like necrosis and autophagy in breast cancer cells.19
Thus, our synthesized mor-nio were able to deliver the drug
into cancer cells by enhanced permeation and retention (EPR)
eﬀect for maximizing the therapeutic eﬀects of morusin even
in a drug resistant cell line and cause its inhibition while
reducing systemic toxicity. A high level of receptor expression-
EGFR, insulin growth factor receptor-1 (IGF-1R), folate, CXCR4
has been reported in TNBC tissues66 which may also be the
mode of action by which morusin mediated toxicity in MDA-
MB-453, however this remains to be conrmed by further
studies.
Epithelial ovarian cancer (EOC), remains the leading cause
of death among gynecological malignant tumors.67 Chemo-
resistance and treatment failure oen occurs due to cellular
resistance to apoptosis, thereby compounds, which may treat
the tumor other than by inducing apoptosis, may provide
a better insight in treating EOC. Recently, morusin was shown
to kill ovarian cells by paraptosis rather than inducing
apoptosis.67 It was also shown to inhibit colony formation in
EOC cells occurring due to the dual eﬀect of cell death and cell
proliferation inhibition. However, caspase -3 nor -9 were found
to be inactivated by morusin in EOC ruling out apoptosis
mediated death. In our study, though signicant toxicity was
observed, SKOV-3 cells were the most resistant of the cell lines
under study. Thus, it is presumed that morusin can activate
diverse cell death pathways depending on diﬀerent cancer cell
types, which explains our cytotoxicity data, with sensitivity of
diﬀerent cancer types to morusin inhibition.
The enhancement of cell death within 24 h treatment of
morusin niosomes compared to free morusin may be due to the
advantage of nanoparticulate mode of drug delivery. Also it has
been seen that use of span 60 as a surfactant has been known to
increase the anti-tumor action of the drug.68 Since nanoscale
particles are easy to internalize within cells, increased drug
retention could be achieved. The cytotoxicity data implies that
mor-nio can competitively demonstrate excellent anticancerous
eﬀect than free morusin.
Live/dead viability assay
In order to analyze activation of apoptosis in cancer cells when
treated with morusin niosomes, we performed live/dead
viability assay to visualize early apoptotic and necrotic cells.
The viability of cells was analyzed post 24 h using live dead
viability staining. EthD-1 enters dead cells via the damaged
membrane, binds to their nuclei, and releases red uorescence
while live cells enzymatically convert calcein AM in uorescent
calcein which emits green uorescence. 500 mg ml1 concen-
tration was suﬃcient to elicit cytotoxicity to cancer cells as
conrmed by cytotoxicity analysis therefore the same concen-
tration was utilized for this assay. Signicant number of dead
cells could be observed with morusin loaded niosome treated
groups compared to free drug at the same concentration (Fig. 6).
In case of HT-29 and MDA-MB-453, when cells were treated
with free morusin, a large number of viable cell population
(Fig. 6b0 and j0) could be observed with some necrotic cells –
(Fig. 6c0 and k0) as well. Compared to free morusin, signicant
amount of dead cells were observed when cells were treated with
mor-nio (Fig. 6c* and k*) as established by enhanced uores-
cent intensity of Etbr (red). Similar eﬀects could be observed in
PANC-1- (Fig. 6g*), however the uorescent intensity of Etbr was
comparatively less compared to HT-29 and MDA-MB-453 which
can be conrmed by cytotoxicity analysis wherein at 500 mgml1
concentration, cell viability for mor-nio was 48.1% for HT-29
and 50.17% for MDA-MB-453 while for PANC-1 it was 61.65%
aer 24 h. However, in case of SKOV-3, both morusin (Fig. 6o0)
and mor-nio (Fig. 6o*) had similar eﬀect on the cells but the red
uorescence coming from the dead cells was more pronounced
This journal is © The Royal Society of Chemistry 2018 RSC Adv., 2018, 8, 32621–32636 | 32631
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Fig. 6 Therapeutic eﬃcacy of morusin loaded, free morusin and void niosomes against cancer cell lines using Live/Dead Assay. The control cells
and cells treated with void niosomes were live as evident by the green ﬂuorescence. The cells treated with morusin niosomes showed
considerable toxicity with minimal number of live cells and increased amount of dead cells (red ﬂuorescence) compared to free morusin where
there were both viable and dead cell populations. Scale bars represent 500 mm.
32632 | RSC Adv., 2018, 8, 32621–32636 This journal is © The Royal Society of Chemistry 2018
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Fig. 7 Molecular docking studies showing interaction between the metalloproteinases (MMP-9 and MMP-2) and morusin. (a and b) It shows the
amino acid residues of MMP-9 interacting with morusin (c and d) Probable binding pocket for morusin on MMP-2 and its interacting residues,
which help in attaining stable conformational state via polar and non-polar interactions.
This journal is © The Royal Society of Chemistry 2018 RSC Adv., 2018, 8, 32621–32636 | 32633
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in the case of mor-nio as inferred from cytotoxicity data where
cell viability aer 24 h was 77.45% when free drug was used and
70.78% when cells were treated with mor-nio. Both control cells
(Fig. 6d, h, l and p) and cells that were treated with void nio
(Fig. 6d00, h00, l00 and p00) showed higher percentage of live cells as
evident by high green uorescent intensity thus indicative of the
healthy state of cells and establishing that cell death was
induced by the drug and not by the niosome nano-carrier. The
results provide visual quantitative support to the cytotoxicity
observations that mor-nio could induce cytotoxic eﬀects in
cancer cells.
Docking studies
It has been reported by a number of studies that morusin exerts
its inhibitory eﬀect on cancer cells by inhibiting one or two key
molecules, which are required for cancer pathogenesis like
STAT-3 and NF-kB pathways. The inhibition of the matrix met-
alloproteinases gelatinases (MMP-2 and MMP-9) by morusin
has also been described in literature.20,24,25 Also, there is an
elevation of these MMPs in colorectal cancer, pancreatic cancer,
ovarian cancer and breast cancer as discussed previously. Thus,
in order to check whether there was any interaction between
morusin and MMPs, we performed molecular docking studies
using Autodock tool. The study showed that the MMPs inter-
action with morusin was inuenced by hydrogen bonding with
active site residues. We performed blind docking study to get an
unbiased estimate of the binding site for morusin on MMPs.
The Gibbs free binding energy (DG) of the MMP-9 morusin
complex was DG ¼ 7.35 kJ mol1 with inhibitory constant (Ki)
value of 4.09 mM. Whereas, for MMP-2 morusin complex DG ¼
8.33 kJ mol1 with Ki value of 786.78 nM. In case of MMP-9-
morusin complex, there was H-bonding of Tyr 393 with mor-
usin while Tyr 423 was engaged in cationic-pi interactions. Leu
187, Met 422 and His 401 provided the hydrophobic interac-
tions. There was no interaction between morusin and Zn of
MMPs (Fig. 7a and b). In case of MMP-2, active site amino acids
Asn 111, Asn 55 and His 193 were engaged in polar contact with
morusin, while Tyr 182 was found to have cation-pi interactions.
Pro 105 and Leu 190 were the two amino acid residues
responsible for the hydrophobic interactions between theMMP-
2-morusin complexes (Fig. 7c and d). This is the rst compu-
tational study to show the probable binding interaction site for
morusin on MMPs.
Conclusion & future perspectives
The present research work details the development of morusin
loaded niosomal nano-formulation for cancer inhibition. The
therapeutic eﬃcacy was imparted by morusin, which is a potent
naturally derived chemotherapeutic agent as conrmed by the
results presented in this report. The particles, with an average
size of 479 nm, displayed high drug loading and encapsulation
eﬃciencies, in addition to rendering aqueous dispersibility to
the usually hydrophobic morusin. A steady and sustained drug
release could be observed for morusin from the niosomes
along-with increased release in acidic pH thus not only
proposing its eﬃcient release in the acidic environment of
cancer cells, but additionally reducing the spontaneous drug
release under physiological pH of normal cells. The toxicity of
morusin niosomes was tested against 4 cancer cell lines of
diﬀerent lineages to assess the degree of toxicity depending on
the cell lineage. According to our study, the cancer cells
susceptibility to mor-nio treatment was in the following order:
HT-29>MDA-MB-453>PANC-1>SKOV-3. Our ndings suggest
that, regardless of the cell type or origin, all the cells under
investigation were highly susceptible to the nano formulation in
a concentration dependent manner, predicting the utilization
of this morusin-niosomal nanoformulation for multiple types of
cancers. Morusin-nio was able to inhibit the survival of MDA-
MB-453, which is a highly drug resistant triple negative breast
cancer cell line. We also performed docking studies to analyze
probable binding of morusin with MMPs. We anticipate that
morusin loaded niosomes will open new scenarios for precise
delivery of morusin to cancer sites as well as lay foundation for
the development of novel targeted therapies in future.
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